Recurrent Head and Neck Squamous Cell Carcinoma Recruiting Phase 1 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0057896 (Recurrent Head and Neck Squamous Cell Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04290546CIML NK Cell in Head & Neck CancerTreatment